Related Experiment Video
Updated: Jan 10, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous
Florentia Dimitriou1, Xiaogang Wu2, Priyadharsini Nagarajan3
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Conjunctival melanoma (CJM) is a rare and aggressive malignancy. Mainly attributed to its rarity, the genomic features of CJM have not been well characterized. In the present study, we sequenced the exomes of primary and metastatic CJM tumors with the aim to unravel their genomic landscape. The results of the study suggest that CJM is a molecularly distinct melanoma subtype with mixed genotype and targetable mutations. Notably, there were features overlapping with both mucosal, and mainly cutaneous melanoma. Of note, some genetic alterations were found in association with specific subsets of CJM, such as bulbar anatomical localization. CJM tumors had intermediate tumor mutational burden, which was significantly higher compared to most cancers included in the cancer genome atlas (TCGA) project and suggest a role for immune checkpoint inhibitor treatment in patients with locally advanced or metastatic disease. These data allow for a better evaluation of the therapeutic options for CJM.
Insights
Conjunctival melanoma (CJM) is a rare cancer. Genomic analysis reveals CJM is distinct, with targetable mutations and features similar to cutaneous melanoma, suggesting new therapeutic strategies.
Area of Science:
- Oncology
- Genomics
- Ophthalmology
Background:
- Conjunctival melanoma (CJM) is a rare and aggressive malignancy.
- The genomic landscape of CJM remains largely uncharacterized due to its rarity.
Purpose of the Study:
- To comprehensively analyze the genomic features of primary and metastatic conjunctival melanoma.
- To identify potential therapeutic targets and understand the molecular distinctiveness of CJM.
Main Methods:
- Whole-exome sequencing of primary and metastatic CJM tumors.
- Comparative genomic analysis against established cancer datasets.
Main Results:
- CJM presents a distinct molecular profile with a mix of genotypes and actionable mutations.
- Genomic features overlap with both mucosal and cutaneous melanoma subtypes.
- Specific genetic alterations correlate with anatomical location, like bulbar conjunctiva.
- CJM exhibits an intermediate tumor mutational burden, higher than many cancers in TCGA.
Conclusions:
- Conjunctival melanoma is a molecularly distinct subtype with therapeutic vulnerabilities.
- The findings support the potential efficacy of immune checkpoint inhibitor therapy for advanced or metastatic CJM.
- This genomic characterization aids in evaluating and optimizing treatment strategies for CJM patients.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...